Chronic hepatitis B virus (HBV) infection remains a burden for many countries around the world, as it is a leading cause of end-stage liver disease and mortality[1-2]. Approximately one third of the world's population has had a previous HBV infection, while 350 to 400 million people are chronically infected with HBV[1-3]. However, the Institute of Medicine Committee states that 65% of these chronically infected HBV patients are unaware of their infection because it does not show any symptoms until it has reached an advanced stage of infection. liver disease. Since HBV can be asymptomatic in the early stages, screening and blood tests are performed to initiate early treatment options for patients. Currently available treatments for the management of HBV are interferon alfa therapy, nucleoside therapy and nucleoside analogues. One of the treatments available for patients with HBV is interferon alfa therapy. It is administered subcutaneously. There are two types of interferon treatment: standard alfa (IFN) and pegylated interferon (PEG-IFN) treatment. According to Bhattacharya et al[1], although both treatments aim to limit viral spread in patients with hepatitis B antigen positive or negative, it has been reported that PEG-IFN is preferred because it further decreases the level of HBV DNA than IFN. Similarly, Papatheodoridis G et al[2] also agree that PEG-IFN is preferred over IFN. In fact, the report states that IFN is replaced by PEG-IFN, because PEG-IFN lacks resistance to antivirals and is able to maintain an undetectable level of HBA DNA in a prolonged off-treatment response[2]. Additionally, PEG-IFN is more patient-friendly because it is only administered once a week, unlike IFN which must be administered several times a week. However, PEG-IFN is not suitable... middle of paper ...... to treat HBV, only a few agents have been shown to be effective and safe because "viral resistance limits their long-term success", as cited by Scaglione S[3]. It is clear that additional studies need to be carried out in order to overcome the resistance barrier of the virus. Additionally, healthcare sectors should strive to educate the public so that they are fully aware of HBV management. Works Cited Bhattacharya D, Thio C. Review of hepatitis Btherapists. Clinical infectious diseases. 2010;51(10):1201--1208.2. Papatheodoridis G, Buti M, Cornberg M, LA H, Janssen D, Pol S et al. Corrigendum to the EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection [J Hepatol 2012; 57: 167-185]. Journal of Hepatology. 2013;58:201.3. Scaglione S, Lok A. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology. 2012;142(6):1360--1368.